Read more

February 03, 2020
2 min read
Save

Patient height may not determine optimal glenosphere size for reverse shoulder arthroplasty

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Selection of glenosphere size based on patient height did not improve range of motion or patient-reported outcome measures after reverse shoulder arthroplasty, according to published results.

Researchers separated 589 primary reverse shoulder arthroplasties (Equinoxe, Exactech) into groups based on whether patients had a glenosphere size of 38-mm or 42-mm and calculated predictive accuracy in relation to height and sex for predicting glenosphere size. Researchers compared improvements in active range of motion and patient-reported outcome measures, including American Shoulder and Elbow Surgeons score, Constant score, simple shoulder test score and University of California, Los Angeles score, based on glenosphere size as a function of height.

Patient height and sex had a strong association with surgeon selection of glenosphere size, according to results of a logistic regression analysis. Researchers found surgeons preferentially treated patients with shorter heights with 38-mm glenospheres and patients with taller heights with 42-mm glenospheres. However, results showed glenosphere size and patient height had no statistically significant interaction effect on improvements in range of motion or patient-reported outcome measures.

“Surgeons should consider other variables when selecting a particular glenosphere size, as similar clinical improvements can be expected between 38- and 42-mm implants using a lateralized humeral [reverse shoulder arthroplasty] RSA design,” the authors wrote. – by Casey Tingle

Disclosures: Schoch reports he is a paid consultant and receives royalties from Exactech. Please see the study for all other authors’ relevant financial disclosures.